Specific immunotherapy of IgE dependent allergy to weed pollen (Perosall C), trees (Perosall D) and grass (Perosall T13), confirmed by skin test and presence of specific antibodies in children and adults.
Composition:
Perosall C: a mixture of pollen allergens, mugwort, white quail, plantain and ordinary sorrel. The kit for basic treatment contains: concentration "1" - 10 JS / ml, concentration "2" - 100 JS / ml, concentration "3" - 1000 JS / ml, concentration "4" - 5000 JS / ml. The maintenance kit contains: concentration "4" - 5000 JS / ml. The set for individual orders includes: concentration "0" - 1 JS / ml.Perosall D: a mixture of allergens of alder pollen, birch and common hazel. The kit for basic treatment contains: concentration "1" - 10 JS / ml, concentration "2" - 100 JS / ml, concentration "3" - 1000 JS / ml, concentration "4" - 5000 JS / ml. The maintenance kit contains: concentration "4" - 5000 JS / ml. The set for individual orders includes: concentration "0" - 1 JS / ml.Perosall T13A mixture of allergens pollen, rye grass, meadow grass tendrils, sweet Corn, broom cereal, tall ryegrass, common rump, common grasshopper, meadow fever, woolly pollen, persistent ryegrass, timothy grass and greenery. The kit for basic treatment contains: concentration "1" - 10 JS / ml, concentration "2" - 100 JS / ml, concentration "3" - 1000 JS / ml, concentration "4" - 5000 JS / ml. The maintenance kit contains: concentration "4" - 5000 JS / ml. The set for individual orders includes: concentration "0" - 1 JS / ml.
Action:
Immunotherapy with the preparation consists in systematic administration of increasing doses of allergen in order to create a tolerance state for a sensitizing allergen. The mechanism of action is to inhibit the formation of specific IgE antibodies, while stimulating the production of IgG. This leads to alleviation or resolution of clinical symptoms during the natural exposure to the allergen.
Contraindications:
Hypersensitivity to any of the excipients. Autoimmune diseases. Cancers. Active tuberculosis. Continuous treatment with β-blockers (eg coronary heart disease, high blood pressure). Clinically overt severe immune deficiencies. Lack of cooperation on the part of the patient. acute infectious diseases with fever (desensitization can be resumed 5-7 days after the infection has disappeared). Exacerbation of chronic infections (desensitization can be resumed 5-7 days after the acute exacerbation). Unstable cardiovascular diseases (requiring periodic use of β-blockers or ACE inhibitors). Severe, unstable asthma - with measurements in spirometry - FEV1 less than 70% of the value due. Severe atopic dermatitis in exacerbation. Age below 5 years.
Precautions:
The preparations used in immunotherapy are always potentially dangerous for patients especially particularly hypersensitive. On the day of application, excessive effort, drinking alcohol and overheating (eg sauna, hot shower) should be avoided.
Pregnancy and lactation:
Due to the lack of documented clinical data, the potential risk for the mother and the fetus is unknown. Specific immunotherapy should not be initiated during pregnancy and breast-feeding. If the treatment was started before pregnancy, it can be continued in consultation with the treating physician.
Side effects:
Throat itching, burning in the mouth, swelling of lips, gastrointestinal disturbances, asthma exacerbation, generalized urticaria, worsening of rhinitis and conjunctivitis, abdominal pain, diarrhea, generalized pruritus may occur.
Dosage:
The preparation should be used before the pollen season, in the asymptomatic period. Basic treatment. Immunotherapy should start at the lowest concentration. The following dosage should be considered as a guide and example of treatment. Treatment can be modified depending on the patient's condition and response to treatment. The preparation should be used daily, in doses increased by 1 drop each day, until reaching 10 drops in the administered concentration (concentrations "1", "2" and "3").After reaching the "4" concentration, the dose should be increased each day by 2 drops, until 10 drops are achieved. For patients who are particularly hypersensitive to pollen allergens, the basic treatment can be started with a concentration of "0". If treatment has been discontinued for more than 2 weeks, it should be started from the half of the last dose administered. If the immunotherapy has been discontinued for more than 4 weeks, desensitization should begin with a concentration of 1. If allergic symptoms occur, the dose should be reduced using less or less concentration for at least 3 days. Then, increase the dose by 1 drop every day according to the basic treatment regimen.Maintenance treatment. The maximum well-tolerated dose should be used twice a week. Treatment should be completed 2-3 weeks before the pollen season. Sublingual, fasting, at least 15 min. before meals.
(C)
